JJP Biologics Reports Positive Phase 1b Data for First-in-Class Anti-CD89 Antagonist in Rare Autoimmune Disease
核心洞察
JJP Biologics (搜索) announced positive interim Phase 1b data for nebaprubart (搜索) (JJP-1212), a first-in-class anti-CD89 (搜索) antagonist, showing favorable safety and rapid clinical activity in Linear IgA Disease (搜索) patients.
Therapeutic effects were observed within one week of dosing, including reduced blister formation and progressive healing of ulcerative lesions, with patients able to taper immunosuppressive therapy.
The results support expansion into rheumatoid arthritis (搜索) trials in Q3 2026 and IgA nephropathy (搜索) studies in Q4 2026, positioning nebaprubart (搜索) as a potential therapy across IgA-mediated diseases.
JJP Biologics (搜索) has announced positive interim data from its ongoing Phase 1b trial of nebaprubart (搜索) (JJP-1212), a first-in-class anti-CD89 (搜索) antagonist, in patients with Linear IgA Disease (搜索) (LAD), a rare autoantibody-mediated skin condition with no approved therapies in the European Union. The results demonstrate encouraging safety and tolerability alongside rapid clinical benefit, including the potential to reduce or eliminate reliance on chronically-administered immunosuppressive therapy.
Rapid Clinical Response Observed
The interim results showed clinical activity with therapeutic effects observed within one week of dosing. Patients experienced reductions in blister formation and pruritus, together with progressive healing of ulcerative lesions. Notably, patients were able to continue tapering dapsone-based treatment after the first dose of JJP-1212, with sustained responses maintained after complete tapering.
The Phase 1b study demonstrated a favorable safety and tolerability profile consistent with Phase I outcomes in healthy volunteers, with no dose-limiting toxicities observed. The trial showed predictable pharmacology, reducing clinical development risk for future studies.
Mechanism of Action Validation
LAD was selected as JJP Biologics (搜索)' first autoimmune disease indication because deposits of IgA autoantibodies in the skin are known to activate neutrophils via CD89 (搜索), leading to tissue damage and widespread skin blistering that can progress to open sores affecting mucous membranes. By blocking the CD89 receptor present on neutrophils, nebaprubart (搜索) interrupts this pathway at its source, restoring tissue integrity and preventing blister formation.
"The interim Phase 1b results in LAD, together with our previously reported Phase I data in healthy volunteers, provide early validation of our approach targeting the IgA/CD89 (搜索) axis," said Paweł Szczepański, Chief Executive Officer of JJP Biologics (搜索). "LAD is our proof-of-mechanism showcase, and these positive interim data demonstrate the potential of nebaprubart (搜索) to deliver rapid, durable responses while reducing dependence on traditionally-administered immunosuppressive agents with known toxicities."
Expansion Plans Across IgA-Mediated Diseases
The positive results position nebaprubart (搜索) as a potentially transformative therapy across a broad range of IgA-mediated diseases. JJP Biologics (搜索) plans to commence a Phase 1b trial of nebaprubart for rheumatoid arthritis (搜索) in Q3 2026 and a Phase 2a basket study in IgA nephropathy (搜索) in Q4 2026.
Sohail Ahmed, MD, MBA, Chief Medical Officer of JJP Biologics (搜索), noted: "The consistency between the safety profile observed in healthy volunteers and the early efficacy and tolerability signals seen in LAD patients is very encouraging. In LAD, the tapering or elimination of other treatments that are difficult for some patients to tolerate is highly meaningful for this patient population."
Study Design and Regulatory Status
The Phase 1b study is registered in the EU Clinical Trials Information System under EU Trial Number 2023-508661-33-00. The open-label trial is designed to evaluate safety and tolerability along with pharmacokinetic, immunogenicity, and exploratory efficacy measures including disease activity, blister formation, and quality of life.
Nebaprubart (搜索) was designated an Orphan Medicinal Product in October 2022 by the European Commission for the treatment of Linear IgA Disease (搜索). The drug is being developed to treat a wide range of autoimmune, inflammatory, and fibrotic diseases where IgA antibodies have significant pathogenic involvement, including rheumatoid arthritis (搜索), systemic lupus erythematosus (搜索), idiopathic pulmonary fibrosis (搜索), dermatitis herpetiformis (搜索), inflammatory bowel disease (搜索), IgA nephropathy (搜索), and IgA vasculitis (搜索).